Toolbox for retrovectorologists

Journal of Gene Medicine

Volumn 6, Issue SUPPL. 1, 2004, Pages

  Pages J C ^a   Bru, Thierry ^a  

^a UNIVERSITÉ DE TOURS   (France)

Author keywords

Biosafety; Gene therapy; Retrovirus; Vector

Indexed keywords

ALANINE AMINOTRANSFERASE; DOUBLE STRANDED DNA; GENOMIC RNA; GLYCOPROTEIN; INTEGRASE; LENTIVIRUS VECTOR; MATRIX PROTEIN; NUCLEOCAPSID PROTEIN; RECOMBINANT RNA; RETROVIRUS VECTOR; RNA DIRECTED DNA POLYMERASE; VIRUS PROTEIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; BIOSAFETY; CD34 SELECTION; CELL BASED GENE THERAPY; CLINICAL TRIAL; COMBINED IMMUNODEFICIENCY; DRUG PACKAGING; EX VIVO STUDY; GENE EXPRESSION REGULATION; GENE TARGETING; HUMAN; IN VIVO STUDY; LEUKEMOID REACTION; LIFE CYCLE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS CAPSID; VIRUS CELL INTERACTION; VIRUS RECOMBINANT; WILD TYPE; ANIMAL; CHEMISTRY; GENE THERAPY; GENE VECTOR; PHYSIOLOGY; RETROVIRUS; SAFETY; STANDARD;

UNIDENTIFIED RETROVIRUS;

ANIMALS; GENE THERAPY; GENETIC VECTORS; HUMANS; MUTAGENESIS, INSERTIONAL; RETROVIRIDAE; SAFETY;

EID: 4644311995     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.498     Document Type: Review

References (164)

1. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000; 288: 669-672.
2. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302: 415-419.
3. Mann R, Mulligan RC, Baltimore D. Construction of a retrovirus packaging mutant and its use to produce helper free defective retrovirus. Cell 1983; 33: 153-159.
4. Watanabe S, Temin HM. Construction of a helper cell line for avian reticuloendotheliosis virus cloning vectors. Mol Cell Biol 1983; 3: 2241-2249.
5. Roe T, Reynolds TC, Yu G, Brown PO. Integration of murine leukemia virus DNA depends on mitosis. EMBO J 1993; 12: 2099-2108.
6. Towers GJ, Hatziioannou T, Cowan S, Goff SP, Luban J, Bieniasz PD. Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors. Nat Med 2003; 9: 1138-1143.
7. Hatziioannou T, Cowan S, Goff SP, Bieniasz PD, Towers GJ. Restriction of multiple divergent retroviruses by Lv1 and Ref1. EMBO J 2003; 22: 385-394.
8. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002; 418: 646-650.
9. Besnier C, Takeuchi Y, Towers G. Restriction of lentivirus in monkeys. Proc Natl Acad Sci U S A 2002; 99: 11 920-11 925.
10. Buchschacher GL Jr, Wong-Staal F. Development of lentiviral vectors for gene therapy for human diseases. Blood 2000; 95: 2499-2504.
11. Merten OW, Cruz PE, Rochette C, et al. Comparison of different bioreactor systems for the production of high titer retroviral vectors. Biotechnol Prog 2001; 17: 326-335.
12. Coffin MJ, Hughes HS, Varmus HE. Retroviruses. CSHL Press: 1997.
13. Charneau P, Alizon M, Clavel F. A second origin of DNA plus-strand synthesis is required for optimal human immunodeficiency virus replication. J Virol 1992; 66: 2814-2820.
14. Lavillette D, Maurice M, Roche C, Russell SJ, Sitbon M, Cosset FL. A proline-rich motif downstream of the receptor binding domain modulates conformation and fusogenicity of murine retroviral envelopes. J Virol 1998; 72: 9955-9965.
15. Lavillette D, Ruggieri A, Russell SJ, Cosset FL. Activation of a cell entry pathway common to type C mammalian retroviruses by soluble envelope fragments. J Virol 2000; 74: 295-304.
16. Bukrinskaya A, Brichacek B, Mann A, Stevenson M. Establishment of a functional human immunodeficiency virus type 1 (HIV-1) reverse transcription complex involves the cytoskeleton. J Exp Med 1998; 188: 2113-2125.
17. Goff SP. Intracellular trafficking of retroviral genomes during the early phase of infection: viral exploitation of cellular pathways. J Gene Med 2001; 3: 517-528.
18. Liu B, Dai R, Tian CJ, Dawson L, Gorelick R, Yu XF. Interaction of the human immunodeficiency virus type 1 nucleocapsid with actin. J Virol 1999; 73: 2901-2908.
19. Stoye JP. Fv1, the mouse retrovirus resistance gene. Rev Sci Technol 1998; 17: 269-277.
20. Trono D. Partial reverse transcripts in virions from human immunodeficiency and murine leukemia viruses. J Virol 1992; 66 4893-4900.
21. Linial ML. Foamy viruses are unconventional retroviruses. J Virol 1999; 73: 1747-1755.
22. Goulaouic H, Subra F, Mouscadet JF, Carteau S, Auclair C. Exogenous nucleosides promote the completion of MoMLV DNA synthesis in GO-arrested Balb c/3T3 fibroblasts. Virology 1994; 200: 87-97.
23. Zack JA, Arrigo SJ, Weitsman SR, Go AS, Haislip A, Chen IS. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 1990; 61: 213-222.
24. Bushman FD. Host proteins in retroviral cDNA integration. Adv Virus Res 1999; 52: 301-317.
25. Farnet CM, Bushman FD. HIV-1 cDNA integration: requirement of HMG I(Y) protein for function of preintegration complexes in vitro. Cell 1997; 88: 483-492.
26. Nakielny S, Dreyfuss G. Transport of proteins and RNAs in and out of the nucleus. Cell 1999; 99: 677-690.
27. Kukolj G, Katz RA, Skalka AM. Characterization of the nuclear localization signal in the avian sarcoma virus integrase. Gene 1998; 223: 157-163.
28. Kukolj G, Jones KS, Skalka AM. Subcellular localization of avian sarcoma virus and human immunodeficiency virus type 1 integrases. J Virol 1997; 71: 843-847.
29. Humphries EH, Glover C, Reichmann ME. Rous sarcoma virus infection of synchronized cells establishes provirus integration during S-phase DNA synthesis prior to cellular division. Proc Natl Acad Sci U S A 1981; 78: 2601-2605.
30. Katz RA, Greger JG, Darby K, Boimel P, Rall GF, Skalka AM. Transduction of interphase cells by avian sarcoma virus. J Virol 2002; 76: 5422-5434.
31. Heinzinger NK, Bukinsky MI, Haggerty SA, et al. The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc Natl Acad Sci U S A 1994; 91: 7311-7315.
32. Bukrinsky MI, Haggerty S, Dempsey MP, et al. A nuclear localization signal within HIV1 matrix protein that govern infection of non-dividing cells. Nature 1993; 365: 666-669.
33. Gallay P, Swingler S, Aiken C, Trono D. HIV 1 infection of non dividing cells: C-terminal tyrosine phosphorylation of the viral matrix protein is a key regulator. Cell 1995; 80: 379-388.
34. Gallay P, Swingler S, Song J, Bushman F, Trono D. HIV nuclear import is governed by the phosphotyrosine-mediated binding of matrix to the core domain of integrase. Cell 1995; 83: 569-576.
35. Gallay P, Stitt V, Mundy C, Oettinger M, Trono D. Role of the karyopherin pathway in human immunodeficiency virus type 1 nuclear import. J Virol 1996; 70: 1027-1032.
36. Gallay P, Hope T, Chin D. Trono D. HIV-1 infection of nondividing cells through the recognition of integrase by the importin/karyopherin pathway. Proc Natl Acad Sci U S A 1997; 94 9825-9830.
37. Zennou V, Petit C, Guetard D, Nerhbass U, Montagnier L, Charneau P. HIV-1 genome nuclear import is mediated by a central DNA flap. Cell 2000; 101: 173-185.
38. Dvorin JD, Bell P, Maul GG, Yamashita M, Emerman M, Malim MH. Reassessment of the roles of integrase and the central DNA flap in human immunodeficiency virus type 1 nuclear import. J Virol 2002; 76 12 087-12 096.
39. Limon A, Nakajima N, Lu R, Ghory HZ, Engelman A. Wild-type levels of nuclear localization and human immunodeficiency virus type 1 replication in the absence of the central DNA flap. J Virol 2002; 76: 12 078-12 086.
40. Sutton RE, Reitsma MJ, Uchida N, Brown PO. Transduction of human progenitor hematopoietic stem cells by human immunodeficiency virus type 1-based vectors is cell cycle dependent. J Virol 1999; 73 3649-3660.
41. Yuan B, Campbell S, Bacharach E, Rein A, Goff SP. Infectivity of Moloney murine leukemia virus defective in late assembly events is restored by late assembly domains of other retroviruses. J Virol 2000; 74: 7250-7260.
42. Yuan B, Fassati A, Yueh A, Goff SP. Characterization of Moloney murine leukemia virus p12 mutants blocked during early events of infection. J Virol 2002; 76: 10 801-10 810.
43. Li L, Olvera JM, Yoder KE, et al. Role of the non-homologous DNA end joining pathway in the early steps of retroviral infection. EMBO J 2001; 20: 3272-3281.
44. Yoder KE, Bushman FD. Repair of gaps in retroviral DNA integration intermediates. J Virol 2000; 74: 11 191-11 200 [MEDLINE record in process].
45. Ketteler R, Glaser S, Sandra O, Martens UM, Klingmuller U. Enhanced transgene expression in primitive hematopoietic progenitor cells and embryonic stem cells efficiently transduced by optimized retroviral hybrid vectors. Gene Ther 2002; 9: 477-487.
46. Hejnar J, Hajkova P, Plachy J, Elleder D, Stepanets V, Svoboda J. CpG island protects Rous sarcoma virus-derived vectors integrated into nonpermissive cells from DNA methylation and transcriptional suppression. Proc Natl Acad Sci U S A 2001; 98 565-569.
47. Carteau S, Hoffmann C, Bushman F. Chromosome structure and human immunodeficiency virus type 1 cDNA integration: centromeric alphoid repeats are a disfavored target. J Virol 1998; 72: 4005-4014.
48. Zhou H, Rainey GJ, Wong SK, Coffin JM. Substrate sequence selection by retroviral integrase. J Virol 2001; 75: 1359-1370.
49. Jordan A, Defechereux P, Verdin E. The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation. EMBO J 2001; 20: 1726-1738.
50. Schroder AR, Shinn P, Chen H, Berry C, Ecker JR, Bushman F. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 2002; 110: 521-529.
51. Lund AH, Turner G, Trubetskoy A, et al. Genome-wide retroviral insertional tagging of genes involved in cancer in Cdkn2a-deficient mice. Nat Genet 2002; 32: 160-165.
52. Mikkers H, Allen J, Knipscheer P, et al. High-throughput retroviral tagging to identify components of specific signaling pathways in cancer. Nat Genet 2002; 32: 153-159.
53. Dejardin J, Bompard-Marechal G, Audit M, Hope TJ, Sitbon M, Mougel M. A novel subgenomic murine leukemia virus RNA transcript results from alternative splicing. J Virol 2000; 74: 3709-3714.
54. Basyuk E, Galli T, Mougel M, Blanchard JM, Sitbon M, Bertrand E. Retroviral genomic RNAs are transported to the plasma membrane by endosomal vesicles. Dev Cell 2003; 5: 161-174.
55. Saavedra C, Felber B, Izaurralde E. The simian retrovirus-1 constitutive transport element, unlike the HIV-1 RRE, uses factors required for cellular mRNA export. Curr Biol 1997; 7: 619-628.
56. Fischer U, Huber J, Boelens WC, Mattaj IW, Luhrmann R. The HIV-1 Rev activation domain is a nuclear export signal that accesses an export pathway used by specific cellular RNAs. Cell 1995; 82: 475-483.
57. King JA, Bridger JM, Gounari F, et al. The extended packaging sequence of MoMLV contains a constitutive mRNA nuclear export function. FEBS Lett 1998; 434: 367-371.
58. Pollard VW, Malim MH. The HIV-1 Rev protein. Annu Rev Microbiol 1998; 52: 491-532.
59. Pasquinelli AE, Ernst RK, Lund E, et al. The constitutive transport element (CTE) of Mason-Pfizer monkey virus (MPMV) accesses a cellular mRNA export pathway. EMBO J 1997; 16: 7500-7510.
60. Myers EL, Allen JF. Tsg101, an inactive homologue of ubiquitin ligase e2, interacts specifically with human immunodeficiency virus type 2 gag polyprotein and results in increased levels of ubiquitinated gag. J Virol 2002; 76: 11 226-11 235.
61. Ott DE, Coren LV, Chertova EN, Gagliardi TD, Schubert U. Ubiquitination of HIV-1 and MuLV Gag. Virology 2000; 278: 111-121.
62. Freed EO. Viral late domains. J Virol 2002; 76: 4679-4687.
63. Suomalainen M, Garoff H. Incorporation of homologous and heterologous proteins into the envelope of Moloney murine leukemia virus. J Virol 1994; 68: 4879-4889.
64. Rein A, Mirro J, Haynes JG, Ernst SM, Nagashima K. Function of the cytoplasmic domain of a retroviral transmembrane protein: p15E-p2E cleavage activates the membrane fusion capability of the murine leukemia virus Env protein. J Virol 1994; 68: 1773-1781.
65. Fielding AK, Chapel-Fernandes S, Chadwick MP, Bullough FJ, Cosset FL, Russell SJ. A hyperfusogenic gibbon ape leukemia envelope glycoprotein: targeting of a cytotoxic gene by ligand display. Hum Gene Ther 2000; 11: 817-826.
66. Swanstrom R, Wills JW. Synthesis, assembly, and processing of viral proteins. In Retroviruses, Coffin JM, Hughes SH, Varmus HE (eds). Cold Spring Harbor Laboratory Press: 1998; 263-335.
67. Wu X, Wakefield JK, Liu H, et al. Development of a novel translentiviral vector that affords predictable safety. Mol Ther 2000; 2: 47-55.
68. Miller AD, Bonham L, Alfano J, Kiem H-M, Reynolds T, Wolgamot G. A novel murine retrovirus identified during testing for helper virus in human gene transfer. J Virol 1996; 70: 1804-1809.
69. Hatziioannou T, Delahaye E, Martin F, Russell SJ, Cosset FL. Retroviral display of functional binding domains fused to the amino terminus of influenza hemagglutinin. Hum Gene Ther 1999; 10: 1533-1544.
70. Russell SJ, Cosset FL. Modifying the host range properties of retroviral vectors. J Gene Med 1999; 1: 300-311.
71. Wool-Lewis RJ, Bates P. Characterization of Ebola virus entry by using pseudotyped viruses: identification of receptor-deficient cell lines. J Virol 1998; 72: 3155-3160.
72. Uckert W, Willimsky G, Pedersen FS, Blankenstein T, Pedersen L. RNA levels of human retrovirus receptors Pit1 and Pit2 do not correlate with infectibility by three retroviral vector pseudotypes. Hum Gene Ther 1998; 9: 2619-2627.
73. Arai T, Matsumoto K, Saitoh K, et al. A new system for stringent, high-titer vesicular stomatitis virus G protein-pseudotyped retrovirus vector induction by introduction of Cre recombinase into stable prepackaging cell lines. J Virol 1998; 72: 1115-1121.
74. Danos O, Mulligan RC. Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc Natl Acad Sci U S A 1988; 85: 6460-6464.
75. Muriaux D, Mirro J, Harvin D, Rein A. RNA is a structural element in retrovirus particles. Proc Natl Acad Sci U S A 2001; 98: 5246-5251.
76. Chakraborty AK, Zink MA, Hodgson CP. Transmission of endogenous VL30 retrotransposons by helper cells used in gene therapy. Cancer Gene Ther 1994; 1: 113-118.
77. Chakraborty AK, Zink MA, Hodgson CP. Expression of VL30 vectors in human cells that are targets for gene therapy. Biophys Biochem Res Commun 1995; 209: 677-683.
78. Patience C, Takeuchi Y, Cosset FL, Weiss RA. Packaging of endogenous retroviral sequences in retroviral vectors produced by murine and human packaging cells. J Virol 1998; 72: 2671-2676.
79. Miller AD. PA 317 retrovirus packaging cells. Mol Ther 2002; 6: 572-575.
80. Lee M, Kremer E, Perricaudet M. Adenoviral vectors. In Molecular and Cell Biology of Human Gene Therapeutics, Hall C (ed . George Dickson: 1995; 20-32.
81. Cosset F-L, Takeuchi Y, Battini JL, Weiss RA, Collins MKL. High-titer packaging cells producing recombinant retroviruses resistant to human complement. J Virol 1995; 69: 7430-7436.
82. Duisit G, Salvetti A, Moullier P, Cosset FL. Functional characterization of adenoviral/retroviral chimeric vectors and their use for efficient screening of retroviral producer cell lines. Hum Gene Ther 1999; 10: 189-200.
83. Serhan F, Jourdan N, Saleun S, Moullier P, Duisit G. Characterization of producer cell-dependent restriction of murine leukemia virus replication. J Virol 2002; 76: 6609-6617.
84. Kim SH, Yu SS, Park JS, Robbins PD, An CS, Kim S. Construction of retroviral vectors with improved safety, gene expression, and versatility. J Virol 1998; 72: 994-1004.
85. Morgenstern JP, Land H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res 1990; 18: 3587-3596.
86. Accola MA, Strack B, Gottlinger HG. Efficient particle production by minimal Gag constructs which retain the carboxy-terminal domain of human immunodeficiency virus type 1 capsid-p2 and a late assembly domain. J Virol 2000; 74: 5395-5402.
87. Yasuda J, Hunter E, Nakao M, Shida H. Functional involvement of a novel Nedd4-like ubiquitin ligase on retrovirus budding. EMBO Rep 2002; 3: 636-640.
88. Yang Y, Vanin EF, Whitt MA, et al. Inducible high level production of infectious murine leukemia retroviral vector particle pseudotyped with vesicular somatitis virus G envelope protein. Hum Gene Ther 1995; 6: 1203-1213.
89. Yang S, Delgado R, King SR, et al. Generation of retroviral vector for clinical studies using transient transfection. Hum Gene Ther 1999; 10: 123-132.
90. Soneoka Y, Cannon PM, Ramsdale EE, et al. A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res 1995; 23: 628-633.
91. Vanin EF, Cerruti L, Tran N, Grosveld G, Cunningham JM, Jane SM. Development of high-titer retroviral producer cell lines by using Cre-mediated recombination. J Virol 1997; 71: 7820-7826.
92. Murdoch B, Pereira DS, Wu X, Dick JE, Ellis J. A rapid screening procedure for the identification of high-titer retrovirus packaging clones. Gene Ther 1997; 4: 744-749.
93. Onodera M, Yachie A, Nelson DM, Welchlin H, Morgan RA, Blaese RM. A simple and reliable method for screening retroviral producer clones without selectable markers. Hum Gene Ther 1997; 8: 1189-1194.
94. Tafuro S, Zentilin L, Falaschi A, Giacca M. Rapid retrovirus titration using competitive polymerase chain reaction. Gene Ther 1996; 3: 679-684.
95. Towers GJ, Stockholm D, Labrousse-Najburg V, Carlier F, Danos O, Pages JC. One step screening of retroviral producer clones by real time quantitative PCR. J Gene Med 1999; 1: 352-359.
96. Olsen JC, Sechelski J. Use of sodium butyrate to enhance production of retroviral vectors expressing CFTR cDNA. Hum Gene Ther 1995; 6: 1195-1202.
97. Pagès JC, Loux N, Farge D, Briand P, Weber A. Activation of Moloney murine leukemia virus LTR enhances the titer of recombinant retrovirus in psi CRIP packaging cells. Gene Ther 1995; 2: 547-551.
98. Darling D, Hughes C, Galea-Lauri J, et al. Low-speed centrifugation of retroviral vectors absorbed to a particulate substrate: a highly effective means of enhancing retroviral titre. Gene Ther 2000; 7: 914-923.
99. Andreadis ST, Brott D, Fuller AO, Palsson BO. Moloney murine leukemia virus-derived retroviral vectors decay intracellularly with a half-life in the range of 5.5 to 7.5 hours. J Virol 1997; 71: 7541-7548.
100. Andreadis S, Lavery T, Davis HE, Le Doux JM, Yarmush ML, Morgan JR. Toward a more accurate quantitation of the activity of recombinant retroviruses: alternatives to titer and multiplicity of infection [corrected and republished article originally printed in J Virol 2000; 74: 1258-1266]. J Virol 2000; 74: 3431-3439.
101. Feng M, Jackson WH Jr, Goldman CK, et al. Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector. Nat Biotechnol 1997; 15: 866-870.
102. Peng KW, Morling FJ, Cosset FL, Murphy G, Russell SJ. A gene delivery system activatable by disease-associated matrix metalloproteinases. Hum Gene Ther 1997; 8: 729-738.
103. Li KJ, Garoff H. Packaging of intron-containing genes into retrovirus vectors by alphavirus vectors. Proc Natl Acad Sci U S A 1998; 95: 3650-3654.
104. Wahlfors JJ, Xanthopoulos KG, Morgan RA. Semliki Forest virus-mediated production of retroviral vector RNA in retroviral packaging cells. Hum Gene Ther 1997; 8: 2031-2041.
105. Linial ML, Miller AD. Retroviral RNA packaging: sequence requirements and implications. Curr Top Microbiol Immunol 1990; 157: 125-152.
106. Zhao Y, Low W, Collins MK. Improved safety and titre of murine leukaemia virus (MLV)-based retroviral vectors. Gene Ther 2000; 7: 300-305.
107. Mautino MR, Keiser N, Morgan RA. Improved titers of HIV-based lentiviral vectors using the SRV-1 constitutive transport element. Gene Ther 2000; 7: 1421-1424.
108. Torrent C, Berlioz C, Darlix JL. Stable MLV-VL30 dicistronic retroviral vectors with a VL30 or MoMLV sequence promoting both packaging of genomic RNA and expression of the 3′ cistron. Hum Gene Ther 1996; 7: 603-612.
109. Shin NH, Hartigan-O'Connor D, Pfeiffer JK, Telesnitsky A. Replication of lengthened Moloney murine leukemia virus genomes is impaired at multiple stages. J Virol 2000; 74: 2694-2702.
110. Ismail SI, Kingsman SM, Kingsman AJ, Uden M. Split-intron retroviral vectors: enhanced expression with improved safety. J Virol 2000; 74: 2365-2371.
111. Krall WJ, Skelton DC, Yu XJ, et al. Increased levels of spliced RNA account for augmented expression from MFG retroviral vector in hematopoïetic cells. Gene Ther 1996; 3: 37-48.
112. Yu SS, Kim JM, Kim S. High efficiency retroviral vectors that contain no viral coding sequences. Gene Ther 2000; 7: 797-804.
113. Hantzopoulos PA, Sullenger BA, Ungers G, Gilboa E. Improved gene expression upon transfer of the adenosine deaminase minigene outside the transcriptional unit of a retroviral vector. Proc Natl Acad Sci U S A 1989; 86: 3519-3523.
114. Choulika A, Guyot V, Nicolas J-F. Transfer of single gene-containing long terminal repeats into the genome of mammalian cells by a retroviral vector carrying the cre gene and the loxP site. J Virol 1996; 70: 1792-1798.
115. Delviks KA, Hu WS, Pathak VK. Psi-vectors: murine leukemia virus-based self-inactivating and self-activating retroviral vectors. J Virol 1997; 71: 6218-6224.
116. Challita P-M, Kohn DB. Lack of expression from a retroviral vector after transduction of murine hematopoïetic stem cells is associated with methylation in vivo. Proc Natl Acad Sci U S A 1994; 91: 2567-2571.
117. Pannell D, Osborne CS, Yao S, et al. Retrovirus vector silencing is de novo methylase independent and marked by a repressive histone code [In Process Citation]. EMBO J 2000; 19: 5884-5894.
118. Rivella S, Callegari JA, May C, Tan CW, Sadelain M. The cHS4 insulator increases the probability of retroviral expression at random chromosomal integration sites. J Virol 2000; 74: 4679-4687.
119. Yannaki E, Tubb J, Aker M, Stamatoyannopoulos G, Emery DW. Topological constraints governing the use of the chicken HS4 chromatin insulator in oncoretrovirus vectors. Mol Ther 2002; 5(Pt 1 : 589-598.
120. Ferrari G, Salvatori G, Rossi C, Cossu G, Mavilio F. A retroviral vector containing a muscle-specific enhancer drives gene expression only in differentiated muscle fibers. Hum Gene Ther 1995; 6: 733-742.
121. Lotti F, Menguzzato E, Rossi C, et al. Transcriptional targeting of lentiviral vectors by long terminal repeat enhancer replacement. J Virol 2002; 76: 3996-4007.
122. Yu SF, von Ruden T, Kantoff PW, et al. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc Natl Acad Sci U S A 1986; 83: 3194-3198.
123. Couture LA, Mullen CA, Morgan RA. Retroviral vectors containing chimeric promoter/enhancer elements exhibit cell-type-specific gene expression. Hum Gene Ther 1994; 5: 667-677.
124. Paulus W, Baur I, Boyce FM, Breakefield XO, Reeves SA. Self-contained, tetracycline-regulated retroviral vector system for gene delivery to mammalian cells. J Virol 1996; 70: 62-67.
125. Ardavin C, Luthi F, Andersson M, et al. Retrovirus-induced target cell activation in the early phases of infection: the mouse mammary tumor virus model. J Virol 1997; 71 7295-7299.
126. Nguyen TH, Pages JC, Farge D, Briand P, Weber A. Amphotropic retroviral vectors displaying hepatocyte growth factor - envelope fusion proteins improve transduction efficiency of primary hepatocytes. Hum Gene Ther 1998; 9: 2469-2479.
127. Halene S, Kohn DB. Gene therapy using hematopoietic stem cells: Sisyphus approaches the crest. Hum Gene Ther 2000; 11: 1259-1267.
128. Wognum AW, Visser TP, Peters K, Bierhuizen MF, Wagemaker G. Stimulation of mouse bone marrow cells with kit ligand, FLT3 ligand, and thrombopoietin leads to efficient retrovirus-mediated gene transfer to stem cells, whereas interleukin 3 and interleukin 11 reduce transduction of short- and long-term repopulating cells. Hum Gene Ther 2000; 11: 2129-2141 [MEDLINE record in process].
129. Bosch A, McCray PB Jr, Chang SM, et al. Proliferation induced by keratinocyte growth factor enhances in vivo retroviral-mediated gene transfer to mouse hepatocytes. J Clin Invest 1996; 98: 2683-2687.
130. Pagès JC, Andreoletti M, Bennoun M, et al. Efficient retroviral-mediated gene transfer into primary culture of murine and human hepatocytes: expression of the LDL receptor. Hum Gene Ther 1995; 6: 21-30.
131. Deminie CA, Emerman M. Incorporation of human immunodeficiency virus type 1 Gag proteins into murine leukemia virus virions. J Virol 1993; 67: 6499-6506.
132. Deminie CA, Emerman M. Functional exchange of an oncoretrovirus and a lentivirus matrix protein. J Virol 1994; 68 4442-4449.
133. Lieber A, Kay MA, Li ZY. Nuclear import of moloney murine leukemia virus DNA mediated by adenovirus preterminal protein is not sufficient for efficient retroviral transduction in nondividing cells. J Virol 2000; 74: 721-734.
134. Seamon JA, Jones KS, Miller C, Roth MJ. Inserting a nuclear targeting signal into a replication-competent Moloney murine leukemia virus affects viral export and is not sufficient for cell cycle-independent infection. J Virol 2002; 76: 8475-8484.
135. Parveen Z, Krupetsky A, Engelstadter M, Cichutek K, Pomerantz RJ, Dornburg R. Spleen necrosis virus-derived C-type retroviral vectors for gene transfer to quiescent cells. Nat Biotechnol 2000; 18 623-629.
136. Rohdewohld H, Weiher H, Reik W, Jaenisch R, Breindl M. Retrovirus integration and chromatin structure: Moloney murine leukemia proviral integration sites map near DNase I-hypersensitive sites. J Virol 1987; 61: 336-343.
137. Cornetta K, Morgan RA, Anderson WF. Safety issues related to retroviral mediated gene transfer in humans. Hum Gene Ther 1991; 2: 5-14.
138. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003; 348: 255-256.
139. Murre C. Intertwining proteins in thymocyte development and cancer. Nat Immunol 2000; 1: 97-98.
140. Kim R, Trubetskoy A, Suzuki T, Jenkins NA, Copeland NG, Lenz J. Genome-based identification of cancer genes by proviral tagging in mouse retrovirus-induced T-cell lymphomas. J Virol 2003; 77: 2056-2062.
141. Jin YF, Ishibashi T, Nomoto A, Masuda M. Isolation and analysis of retroviral integration targets by solo long terminal repeat inverse PCR. J Virol 2002; 76: 5540-5547.
142. Wu X, Li Y, Crise B, Burgess SM. Transcription start regions in the human genome are favored targets for MLV integration. Science 2003; 300: 1749-1751.
143. Aiuti A, Slavin S, Aker M, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002; 296: 2410-2413.
144. Aiuti A, Vai S, Mortellaro A, et al. Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement. Nat Med 2002; 8: 423-425.
145. Li Z, Dullmann J, Schiedlmeier B, et al. Murine leukemia induced by retroviral gene marking. Science 2002; 296 497.
146. Bonini C, Grez M, Traversari C, et al. Safety of retroviral gene marking with a truncated NGF receptor. Nat Med 2003; 9: 367-369.
147. Weidhaas JB, Angelichio EL, Fenner S, Coffin JM. Relationship between retroviral DNA integration and gene expression. J Virol 2000; 74: 8382-8389.
148. Zaiss AK, Son S, Chang LJ. RNA 3′ read through of oncoretrovirus and lentivirus: implications for vector safety and efficacy. J Virol 2002; 76: 7209-7219.
149. Donahue RE, Kessler SW, Bodine D, et al. Helper virus induced T cell lymphoma in non human primates after retroviral mediated gene transfer. J Exp Med 1992; 176: 1125-1135.
150. Hu WS, Temin HM. Genetic consequences of packaging two RNA genomes in one retroviral particle: pseudodiploidy and high rate of genetic recombination. Proc Natl Acad Sci U S A 1990; 87: 1556-1560.
151. Yang J, Bogerd HP, Peng S, Wiegand H, Truant R, Cullen BR. An ancient family of human endogenous retroviruses encodes a functional homolog of the HIV-1 Rev protein. Proc Natl Acad Sci U S A 1999; 96: 13 404-13 408.
152. Zufferey R, Dull T, Mandel RJ, et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 1998; 72: 9873-9880.
153. Reiser J. Production and concentration of pseudotyped HIV-1-based gene transfer vectors. Gene Ther 2000; 7: 910-913.
154. Aubert D, Menoret S, Chiari E, et al. Cytotoxic immune response blunts long-term transgene expression after efficient retroviral-mediated hepatic gene transfer in rat. Mol Ther 2002; 5: 388-396.
155. Kafri T, Blomer U, Peterson DA, Gage FH, Verma IM. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat Genet 1997; 17: 314-317.
156. Blomer U, Naldini L, Kafri T, Trono D, Verma IM, Gage FH. Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J Virol 1997; 71: 6641-6649.
157. Naldini L, Blömer U, Gallay P, et al. In vivo gene delivery and stable transduction of non-dividing cells by a lentiviral vector. Science 1996; 272: 263-267.
158. Naldini L, Blomer U, Gage FH, Trono D, Verma IM. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci U S A 1996; 93: 11 382-11 388.
159. Kordower JH, Bloch J, Ma SY, et al. Lentiviral gene transfer to the nonhuman primate brain. Exp Neurol 1999; 160: 1-16.
160. Park F, Ohashi K, Chiu W, Naldini L, Kay MA. Efficient lentiviral transduction of liver requires cell cycling in vivo. Nat Genet 2000; 24: 49-52.
161. Clever JL, Taplitz RA, Lochrie MA, Polisky B, Parslow TG. A heterologous, high-affinity RNA ligand for human immunodeficiency virus Gag protein has RNA packaging activity. J Virol 2000; 74: 541-546.
162. Bushman F. Targeting retroviral integration? Mol Ther 2002; 6: 570-571.
163. Kaminski JM, Huber MR, Summers JB, Ward MB. Design of a nonviral vector for site-selective, efficient integration into the human genome. FASEB J 2002; 16: 1242-1247.
164. McLachlin JR, Mittereder N, Daucher MB, Kadan M, Eglitis MA. Factors affecting retroviral vector function and structural integrity. Virology 1993; 195: 1-5.